As recently reviewed by McGowan and colleagues, SphK2 is gaining acceptance as a valid cancer therapeutic target and specific SphK2 modulators (agonists and antagonists) appear to have increased efficacy in clinical trials for cancer treatment [12]. This evidence concerns the gene SPHK2 and cancer.